摘要
目的对依达拉奉联合脑苷肌肽治疗重症颅脑损伤的临床疗效及安全性进行探讨分析。方法选取该院2013年5月—2016年6月就诊的重症颅脑损伤患者共50例,作为该次研究对象,按照治疗方式不同,将这50例患者分为对照组和观察组,每组25例,对照组给予静脉滴注脑苷肌肽注射液10 m L,1次/d,观察组在对照组的基础上,另予静脉滴注依达拉奉30 mg,2次/d,1个周期均为7 d,两组患者共治疗2个周期,比较两组患者临床疗效及不良反应发生情况。结果经过不同方式治疗后两组患者临床疗效比较,对照组为76.0%,观察组为92.0%(P<0.05),治疗后,对照组与观察组不良反应比较,对照组不良反应发生率为20.0%,观察组发生率为12.0%,数据差异无统计学意义(P>0.05)。结论经过依达拉奉联合脑苷肌肽治疗重症颅脑损伤患者临床疗效明显,不良反应发生率低,安全有效。
Objective This paper tries to study the clinical efficacy and safety of edaravone combined with encephalon glycoside and ignotin in the treatment of severe craniocerebral injury. Methods 50 patients with severe craniocerebral injury from May 2013 to June 2016 were selected and divided into the control group and the observation group accord-ing to the different treatment methods with 25 cases in each group, the control group was given intravenous infusion of edaravone of 10ml once per day, the observation group added intravenous infusion of edaravone 30mg twice a day, one cycle of seven days, and the two groups of patients were treated for 2 cycles, and then the clinical efficacy and adverse reactions of the two groups were compared. Results The c lin ica l efficacy of the two groups was 76.0% in the control group and 92.0% in the observation group （P〈0.05）. After the treatment, the adverse reaction rate of the control group was 20.0%, and that of the observation group was 12.0%, the difference was not statistically significant （P〉0.05）. Conclusion The edaravone combined with encephalon glycoside and ignotin in patients with severe craniocerebral injury has obvious curative efficiency, with low adverse reaction rate, safe and effective.
出处
《系统医学》
2017年第13期62-64,共3页
Systems Medicine
关键词
依达拉奉
脑苷肌肽
重症颅脑损伤
安全性
Edaravone
Encephalon glycoside and ignotin
Severe craniocerebral injury
Safety
